Navigation Links
Global Markets for Asthma and COPD Drugs
Date:9/6/2012

NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Global Markets for Asthma and COPD Drugs

http://www.reportlinker.com/p0166826/Global-Markets-for-Asthma-and-COPD-Drugs.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

INTRODUCTION

 

STUDY GOALS AND OBJECTIVES

 

This study is intended to provide readers with an understanding of the global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs. The study outlines the industry structure, competitive aspects, current developments, and future trends in the market, to assist in identifying areas of commercial interest and potential in the asthma and COPD indications.

 

The objectives of the study include the assessment of current market status, the analysis of marketed drugs, market revenues, company shares, unmet market needs, market challenges, and future trends. Future market revenues are forecast for the global market, major drug classes, individual disease indication, and largest geographical regions. The study also reviews the compounds currently being investigated in clinical studies for the treatment of asthma and COPD.

 

REASONS FOR DOING THE STUDY

 

Asthma and COPD are two diseases experiencing increasing prevalence globally due to a combination of factors, including a globally aging population and increasing pollution levels. COPD is one of the top five causes of disability and death in industrialized countries and the fourth-leading cause of death globally.

 

The market for asthma and COPD drugs had global revenues in 2010 that exceeded $34 billion annually. These drugs enjoy tremendous commercial success, as illustrated by the presence of six currently marketed multibillion-dollar drugs in this market. However, there is a perceived high level of unmet need in this market in terms of treatment options for asthma and COPD patients.

 

With the loss of patent protection on several major COPD and asthma drugs between 2010 and 2017, the cost for some treatments is expected to decrease as generic versions gain market share. Additionally, several new drugs are projected to enter the market through 2017, and they will continue to drive growth of revenues for asthma and COPD drugs.

 

SCOPE OF REPORT

 

The report provides a current market overview and projects future developments in the asthma and COPD drugs market over the period from 2011 through 2017. The report describes existing drug classes approved for these indications, such as bronchodilators, anti-inflammatory drugs, and combination drugs of inhaled corticosteroids and bronchodilators. The pipeline of drugs in clinical trials for these indications is also presented and analyzed.

 

The report includes the following major sections:

 

Disease overview.

Industry structure and competitive analysis including tiers of competition; regulatory aspects; competitive factors; and market needs, challenges, and trends

Overall market revenue forecast and current market shares as well as revenue forecast by major drug classes, disease indication, and geographical regions.

In-depth analyses of current drug classes.

Reviews and analyses of compounds in clinical trials, with an emphasis on drugs in advanced stages of development.

 

The report will also analyze product sales and demographics in three regional markets: The Americas (U.S., Canada, Latin/South America); Europe, Middle East, Russia, Africa (EMRA); and Asia (Japan, Australia/New Zealand, other Asian nations, including India and China).

 

METHODOLOGY

 

Both primary and secondary research methodologies were used in preparing this study. The analyses and data presented in this report are based on information collected from a variety of industry sources, including pharmaceutical manufacturers and end users. Secondary information sources include company financials and documentation, U.S. Securities and Exchange Commission (SEC) filings, the U.S. Patent and Trademark Office (USPTO), MEDCO Health, World Health Organization (WHO), trade organizations and their publications, online databases, and the medical and scientific literature.

 

The base year for analysis and forecast is 2011. Revenue forecasts are provided for the period 2012 to 2017. The forecasts are based on a comprehensive analysis of a variety of market and product-specific factors, including historical, current, and future trends; existing and undiagnosed patient populations; unmet market needs; existing product patent expiration dates; the impact of the generic market; and new market entrants and their value proposition and differentiation.

 

Values are given in U.S. dollars, forecasts are made in constant U.S. dollars, and growth rates are compounded. Currency conversions were made in June 2012. Growth rates were calculated based on existing and proposed device and equipment sales, at manufacturer pricing, during the forecast period.

 

INTENDED AUDIENCE

 

This report provides information that is useful for business planners, market researchers, marketers, business developers, investors, venture capitalists, consultants, and anyone who wants to understand or invest in this market. The information is also useful for technology licensing and scientific research and development purposes.

 

INFORMATION SOURCES

 

The analysis and data presented in this report are based on information collected from a variety of industry sources, including the pharmaceutical manufacturers that currently market prescription drugs in this therapeutic area and research- based companies that develop new drug candidates for these indications, as well as end users of prescription drugs. Secondary information sources include company websites, financials, and other literature; SEC filings; patents issued by the USPTO; trade organizations and publications; online databases; and medical and scientific literature.

 

ANALYST CREDENTIALS

 

Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and an MS in Communication from the University of Denver. Ms. Lehr has worked within the publishing industry for both for-profit and not-for-profit organizations, and she has completed more than 20 reports for BCC.

 

 

 

TABLE OF CONTENTS

 

CHAPTER 1 INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 1

METHODOLOGY 2

INTENDED AUDIENCE 2

INFORMATION SOURCES 2

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER 2 SUMMARY 5

SUMMARY TABLE GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY

DISEASE, THROUGH 2017 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY

REGION, 2012 AND 2017 (%) 6

CHAPTER 3 OVERVIEW 9

PULMONARY DRUG DELIVERY 9

PULMONARY CONDITIONS AND THERAPIES 9

RESPIRATORY SYSTEM 9

LUNG 11

Particle Size, Toxicity and Drug Deposition 11

Systemic and Local Therapy 12

Pulmonary Drug Delivery-Devices 12

Device Characteristics 12

Manufacturing Techniques 14

ASTHMA 16

Symptoms of Asthma 17

Global Prevalence 17

CHRONIC OBSTRUCTIVE PULMONARY DISEASE 17

Symptoms of COPD 17

Medication Treatment 18

Types of Medication Treatments 18

Classification of Asthma and COPD Medications 18

Bronchodilators 18

Quick-acting Bronchodilators 18

Two Classes of Long-Term Bronchodilators 19

Anti-inflammatory Drugs 19

Combination Inhaled Corticosteroids and Long-acting Beta-2 Agonists (ICS/LABA) 19

Advantages of ICS/LABA 20

TABLE 1 MARKETED ASTHMA AND COPD DRUG CLASSES 20

Drug Delivery Methods 20

Inhaled Drugs 21

Metered-dose Inhaler 21

Pressurized MDI Devices 21

Types of Metered-dose Inhalers 21

Breath-activated Inhalers 21

Types of Breath-activated Inhalers 22

Dry Powder Inhalers 22

Disadvantages of DPI 22

Types of DPI Inhalers 22

Nebulizers 22

Usage 23

Types of Nebulized Drugs 23

Oral and Injectable Drugs 23

Oral Drug Types 23

Injectable Drug Types 23

ADVANTAGES/DISADVANTAGES OF DRUG DELIVERY METHODS 23

DRUG DEVELOPMENT PROCESS 24

DEVELOPMENT OF DISEASE-MODIFYING DRUGS 24

New Drug Targets 24

TECHNICAL ASPECTS IN THE DEVELOPMENT OF INHALED DRUGS 25

INTELLECTUAL PROPERTY RIGHTS 25

DRUG DEVELOPMENT 25

COMPLEX REGULATORY DRUG APPROVAL PROCESS 26

Approval Times 26

REGULATORY ISSUES 26

REMOVAL OF CFC-PROPELLED INHALERS 26

FDA DRUG SAFETY WARNINGS 27

INDUSTRY PLAYERS 27

TIERS OF COMPETITION 27

MAJOR DRUG MANUFACTURERS 28

GlaxoSmithKline 28

Merck 28

Boehringer Ingelheim 28

TABLE 2 NET REVENUES FOR TOP SIX ASTHMA/COPD PRODUCT MANUFACTURERS, WITH

PRODUCT(S), 2010 AND 2011 ($ MILLIONS) 29

SPECIALTY PHARMACEUTICAL COMPANIES 29

Teva Pharmaceutical 29

Chiesi Farmaceutici 29

Sunovion/Sepracor 30

TABLE 3 NET REVENUES FOR TOP SPECIALTY ASTHMA/COPD MANUFACTURERS WITH

PRODUCT(S), 2010 AND 2011 ($ MILLIONS) 30

SMALLER COMPANIES 30

TABLE 4 NET REVENUES FOR SMALLER ASTHMA/COPD PRODUCT MANUFACTURER, WITH

PRODUCT, 2010 AND 2011 ($ MILLIONS) 30

ACQUISITIONS AND MERGERS 31

TABLE 5 ACQUISITIONS AND MERGERS IN THE ASTHMA AND COPD MARKET, JANUARY

2008 TO JUNE 2012 ($ MILLIONS) 31

COMPETITIVE FACTORS 31

SIX COMPETITIVE FACTORS 31

Delivery Mode and Convenience 32

Product Efficacy and Dosage Frequency 32

Safety 33

Combination Drugs 33

Drug Pricing 33

Sales and Marketing 33

SIGNIFICANT TRENDS 34

GLOBAL AGING POPULATION LEADS TO INCREASING ASTHMA AND COPD

PREVALENCE 34

NEW DRUG LAUNCHES OFFER ENHANCED TREATMENT OPTIONS 34

PATENT EXPIRATIONS OF MAJOR DRUGS AND GENERIC DRUG LAUNCHES WILL

CHANGE THE MARKET 34

TABLE 6 MAJOR ASTHMA/COPD DRUGS THAT LOSE PATENT PROTECTION BETWEEN 2008

AND 2024 35

MARKET CHALLENGES 36

TECHNICAL- AND MARKET-SPECIFIC EXPERTISE REQUIRED TO COMPETE IN THIS

THERAPEUTIC AREA 36

FILLING UNMET NEEDS 36

DISEASE-MODIFYING DRUGS 36

SUPERIOR EFFICACY DRUGS 37

IMPROVED SAFETY PROFILE DRUGS 37

IMPROVED DRUG DELIVERY MODALITIES 37

IMPROVED QUALITY OF LIFE FOR PATIENTS 37

REGIONAL ANALYSIS 38

THE AMERICAS 38

Demographic Findings 38

Asthma and Children in the Americas 38

Loss of Patent Protection 38

Product Usage 39

EMRA 39

Demographic Findings 39

Asthma and Children 39

Product Usage 39

ASIA 40

Demographic Findings 40

Asthma and Children in Asia 40

Product Usage 40

CHAPTER 4 DISEASE OVERVIEW 42

SYMPTOM COMPARISONS 42

TABLE 7 ASTHMA AND COPD SYMPTOM COMPARISONS 42

ASTHMA OVERVIEW 42

ASTHMA IN CHILDREN 42

ASTHMA IN ADULTS 43

GLOBAL ECONOMIC BURDEN OF ASTHMA 43

CLASSIFICATION OF ASTHMA 43

TABLE 8 CLASSIFICATION OF ASTHMA, BY SYMPTOMS 44

CAUSES AND RISK FACTORS 44

DIAGNOSIS 44

Diagnostic Tests 45

Spirometry 45

Peak Flow Test 45

Methacholine Bronchial Challenge Test 45

Nitric Oxide Test 45

Skin or Blood Test 46

DRUG CLASSES APPROVED IN THE TREATMENT OF ASTHMA AND COPD 46

TABLE 9 ASTHMA AND COPD DRUG CLASSES 46

Bronchodilators 46

Anti-inflammatory drugs 46

Combination Therapies of Bronchodilators and Anti-inflammatory Drugs 47

MEDICATION TREATMENT ALGORITHMS 47

First Line Therapy 47

Second Line Therapy 47

CHRONIC OBSTRUCTIVE PULMONARY DISEASE 48

CLASSIFICATION OF COPD 48

TABLE 10 CLASSIFICATION OF COPD AND ASTHMA 49

CAUSES AND RISK FACTORS 49

DIAGNOSIS 49

COPD TREATMENT METHODS 49

Vaccine 49

Rehabilitation 50

Oxygen Therapy 50

Surgery 50

Medication Treatments 50

Drug Selection 51

REGIONAL STATISTICS 51

ACCESS TO CARE 51

AVAILABILITY OF TREATMENTS 52

NORTH AMERICA 52

Asthma in the U.S. 52

Adults and Asthma in the U.S. 52

Asthma in Canada 53

Asthma in Central America 53

Asthma in the Caribbean 53

ASTHMA IN SOUTH AMERICA 54

TABLE 11 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN THE

AMERICAS (%) 54

COPD IN THE U.S. 55

EMRA 55

Asthma in EMRA 55

Scandinavian/Baltic countries 55

Asthma in the UK and Ireland 55

Asthma in Western Europe 56

Asthma in Eastern Europe 56

Asthma in Russia 56

Asthma in the Middle East 57

TABLE 12 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN THE EMRA

(%) 57

COPD in EMRA 58

COPD in Russia 58

ASIA 58

Asthma in Asia 58

Asthma in Central Asia 58

Asthma in Southern Asia 59

Asthma in China/Taiwan/Mongolia 59

Asthma in Northeast Asia 59

Asthma in Southeast Asia 60

Asthma in Oceania 60

TABLE 13 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN ASIA 61

COPD in Asia 61

CHAPTER 5 MARKETS BY DRUG CLASS 63

TABLE 14 PROJECTED GLOBAL MARKET FOR ASTHMA AND COPD DRUG, BY DRUG CLASS,

THROUGH 2017 ($ MILLIONS) 63

BRONCHODILATORS 63

MARKET REVENUES AND FORECAST 63

FIGURE 1 GLOBAL BRONCHODILATOR MARKET, BY TYPE, 2012 AND 2017 (%) 64

TABLE 15 PROJECTED GLOBAL MARKET FOR BRONCHODILATORS, THROUGH 2017 ($

MILLIONS) 65

MANUFACTURERS' MARKET SHARE FOR BRONCHODILATORS 65

FIGURE 2 GLOBAL MARKET SHARE FOR BRONCHODILATORS BY COMPANY, 2011 (%) 65

SHORT-ACTING BETA-2 AGONISTS 66

TABLE 16 SHORT-ACTING BETA-2 AGONISTS, WITH APPROVAL AND PATENT EXPIRY DATES,

2011 67

Market Revenues and Forecast 67

Advantages/Disadvantages 68

TABLE 17 PROJECTED MARKET FOR SHORT-ACTING BETA-2 AGONIST BRONCHODILATORS,

THROUGH 2017 ($ MILLIONS) 68

LONG-ACTING BETA-2 AGONISTS 68

TABLE 18 LONG-ACTING BETA-2 AGONISTS, 2011 69

Market Revenues and Forecast 69

TABLE 19 PROJECTED GLOBAL MARKET FOR LABA PRODUCTS, THROUGH 2017 ($

MILLIONS) 70

FIGURE 3 MARKET SHARE FOR LABA BRONCHODILATORS BY COMPANY, 2011 (%) 70

ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SABA 71

TABLE 20 ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SABA BY

MANUFACTURER, 2011 71

Market Revenues and Forecast 71

TABLE 21 PROJECTED GLOBAL MARKET FOR ANTICHOLINERGICS, THROUGH 2017 ($

MILLIONS) 72

ANTI-INFLAMMATORY DRUGS 72

Market Revenues and Forecast 72

FIGURE 4 MARKET SHARE OF ANTI-INFLAMMATORY DRUGS BY TYPE, 2012 AND 2017 (%) 72

TABLE 22 PROJECTED GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS BY TYPE,

THROUGH 2017 ($ MILLIONS) 74

Inhaled Corticosteroids 74

TABLE 23 INHALED CORTICOSTERIODS, 2011 75

FIGURE 5 MARKET SHARE OF LEADING MANUFACTURERS OF INHALED CORTICOSTERIODS,

2011 (%) 76

Competition in the ICS market 76

TABLE 24 PROJECTED GLOBAL MARKET FOR INHALED CORTICOSTEROIDS, THROUGH 2017

($ MILLIONS) 77

LEUKOTRIENE MODIFIERS 77

TABLE 25 LEUKOTRIENE MODIFIERS, 2011 77

Market Revenues and Forecast 78

TABLE 26 PROJECTED GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, THROUGH 2017 ($

MILLIONS) 78

FIGURE 6 GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, BY MANUFACTURER, 2012

AND 2017 (%) 79

PDE-4 INHIBITORS 80

TABLE 27 PROJECTED GLOBAL MARKET FOR PDE-4 DRUGS, THROUGH 2017 ($ MILLIONS) 80

BIOLOGICAL DRUGS 80

MARKET REVENUES AND FORECAST 80

Increasing Market for Biological Drugs to Treat Asthma 80

TABLE 28 PROJECTED GLOBAL MARKET FOR ASTHMA BIOLOGICAL DRUGS, THROUGH 2017

($ MILLIONS) 81

COMBINATION ICS/LABA DRUGS 81

TABLE 29 COMBINATION ICS/LABA DRUGS, 2011 81

MARKET REVENUES AND FORECAST 82

TABLE 30 PROJECTED GLOBAL MARKET FOR COMBINATION ICS/LABA DRUGS, THROUGH

2017 ($ MILLIONS) 82

FIGURE 7 MARKET SHARE OF MANUFACTURERS OF ICS/LABA, 2011 (%) 83

Market Dynamics 83

Flutiform 84

Dulera 84

Relovair 84

REGIONAL ANALYSIS 84

TABLE 31 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS BY REGION, THROUGH

2017 ($ MILLIONS) 85

The Americas 85

TABLE 32 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE AMERICAS REGION,

THROUGH 2017 ($ MILLIONS) 85

Projected Use of Asthma/COPD Drugs, by Americas' Regions 85

TABLE 33 PROJECTED USE OF ASTHMA/COPD DRUGS IN THE AMERICAS' REGION,

THROUGH 2017 ($ MILLIONS) 86

FIGURE 8 MARKET PERCENT OF ASTHMA/COPD DRUGS IN THE AMERICAS REGION, 2012

AND 2017 (%) 86

EMRA 87

TABLE 34 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE EMRA, THROUGH

2017 ($ MILLIONS) 87

TABLE 35 PROJECTED USE OF ASTHMA/COPD DRUGS IN THE EMRA REGION, THROUGH

2017 ($ MILLIONS) 87

FIGURE 9 MARKET PERCENT OF ASTHMA/COPD DRUGS IN THE EMRA, 2012 AND 2017 (%) 88

Asia 89

TABLE 36 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE ASIAN REGION,

THROUGH 2017 ($ MILLIONS) 89

TABLE 37 PROJECTED USE OF ASTHMA/COPD DRUGS, BY REGION IN ASIA, THROUGH 2017

($ MILLIONS) 89

FIGURE 10 MARKET PERCENTAGE OF ASTHMA/COPD DRUGS, BY REGION IN ASIA, 2012

AND 2017 (%) 89

CHAPTER 6 MARKETS BY DISEASE 92

FIGURE 11 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE,

2011 (%) 92

ASTHMA DRUGS 92

MARKET REVENUES FOR ASTHMA DRUGS 93

MARKET SHARES, BY COMPANY 93

FIGURE 12 MARKET SHARES OF LEADING MANUFACTURERS OF ASTHMA DRUGS, 2011 (%) 93

NEW BRANDED ASTHMA DRUGS LAUNCHES 95

GENERIC DRUG LAUNCHES 95

TABLE 38 PROJECTED GLOBAL MARKET FOR ASTHMA PRESCRIPTION DRUGS, THROUGH

2017 ($ MILLIONS) 96

CHRONIC OBSTRUCTIVE PULMONARY DISEASE 96

FIGURE 13 MARKET SHARES OF LEADING MANUFACTURERS OF COPD DRUGS, 2011 (%) 96

TABLE 39 PROJECTED GLOBAL MARKET FOR COPD PRESCRIPTION DRUGS, THROUGH 2017

($ MILLIONS) 97

BRANDED COPD PRODUCT LAUNCHES 97

COMBINATION ASTHMA/COPD DRUGS 97

TABLE 40 PROJECTED GLOBAL MARKET FOR COMBINATION ASTHMA/COPD DRUGS,

THROUGH 2017 ($ MILLIONS) 98

FIGURE 14 MARKET SHARES OF LEADING MANUFACTURERS OF COMBINATION

ASTHMA/COPD DRUGS, 2011 (%) 98

TABLE 41 PROJECTED GLOBAL MARKET FOR COMBINATION ASTHMA/COPD PRESCRIPTION

DRUGS, THROUGH 2017 ($ MILLIONS) 99

CHAPTER 7 EMERGING TRENDS AND PRODUCT PIPELINE REVIEW 101

THE "ASTHMA GENE" 101

ORAL DRUGS FOR ASTHMA 101

LEUKOTRIENE ORAL DRUGS 101

Masitinib 101

Oral Antifungal Treatment for Severe Asthma 101

DISEASE MODIFYING DRUGS 102

ASTHMA FORMULATIONS 102

COPD FORMULATIONS 102

BOEHRINGER INGELHEIM 102

FOREST LABORATORIES/AMIRALL SA 102

ELEVATION PHARMACEUTICALS 103

PEARL THERAPEUTICS 103

NOVEL BIOLOGICS 103

AMG 157 103

AMG 176 103

MEPOLIZUMAB 103

ULTRA LONG-ACTING MUSCARINIC ANTAGONISTS 103

ULTRA LONG-ACTING B2 AGONISTS (ULTRA-LABA) 104

LAMA AND LABA COMBINATION DRUGS 104

ANTI-INFLAMMATORY DRUGS 105

ANTI-PROTEASE 105

CHEMOKINE ANTAGONISTS 105

PPAR AGONISTS 105

ASTHMA/COPD DRUG DEVELOPMENT, BY COMPANY 105

TABLE 42 ASTHMA/COPD PRODUCTS UNDER DEVELOPMENT, BY COMPANY, 2012 106

ASTHMA DEVICES 108

CHAPTER 8 APPROVED DRUGS AND PATENT REVIEW 110

TABLE 43 APPROVED DRUGS TO TREAT ASTHMA AND COPD, 1996 THROUGH 2011 110

TABLE 44 DRUGS SEEKING APPROVAL TO TREAT ASTHMA AND COPD 2012 THROUGH 2013 111

PATENT REVIEW 111

TABLE 45 ASTHMA/COPD TREATMENT PATENTS, BY COMPANY, DISEASE, PATENT NUMBER,

YEAR FILED, 2011 THROUGH 2012 112

FIGURE 15 PERCENT OF REVIEWED PATENTS FOR ASTHMA, COPD, AND COMBINATION

USE, JANUARY 2011 TO MAY 2012 (%) 114

TABLE 46 ASTHMA/COPD TREATMENT PATENTS, BY NUMBER, COMPANY, DESCRIPTION,

AND DATE ISSUED, 2011 THROUGH 2012 115

TABLE 47 ASTHMA/COPD DRUG TREATMENT PATENTS ISSUED BETWEEN JANUARY 2011

AND MAY 2012, BY COMPANY 123

FIGURE 16 ASTHMA/COPD PATENTS, BY COUNTRY, 2011 THROUGH 2012 (%) 125

CHAPTER 9 COMPANY PROFILES 127

ACTIENT PHARMACEUTICALS 127

AEROVANCE, INC. 127

ALMIRALL, S.A. 128

AMGEN INC. 128

APTAR PHARMA 129

ARGENTA DISCOVERY, LTD. 129

ASTRAZENECA 130

ASTRAZENECA PHARMACEUTICALS, LP 130

BOEHRINGER INGELHEIM GMBH 131

CHIESI FARMACEUTICI SPA 131

CORNERSTONE THERAPEUTICS 132

CYTOS BIOTECHNOLOGY AG 132

DEY PHARMA (MYLAN SPECIALTY L.P.) 133

FOREST LABORATORIES, INC. 133

GENENTECH, INC. (ROCHE) 133

GLAXO WELLCOME U.K., LTD. 134

GLAXOSMITHKLINE U.S. 134

MEDICINOVA 135

MEDICIS PHARMACEUTICAL 136

MEDIMMUNE 136

MERCK & CO., INC. 136

NOVARTIS PHARMA 137

NOVARTIS CORPORATION 137

NOVARTIS PHARMACEUTICALS CORPORATION 137

NYCOMED INTERNATIONAL (TAKEDA INTERNATIONAL) 138

OSIRIS THERAPEUTICS, INC. 139

PFIZER, INC. 139

SEPRACOR, INC. (SUNOVION) 140

SKYEPHARMA PLC 140

TEVA PHARMACEUTICAL INDUSTRIES, LTD. 141

TEVA PHARMACEUTICALS USA 141

THERAVANCE 142

RELOVAIR 142

LAMA/LABA (GSK573719/VILANTROL) 142

BIFUNCTIONAL MUSCARINIC ANTAGONIST-BETA2 AGONIST PROGRAM 142

INHALED LONG-ACTING MUSCARINIC ANTAGONIST (LAMA) 142

TOPIGEN PHARMACEUTICALS, INC. (PHARMAXIS LTD) 143

VECTURA GROUP PLC 143

 

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY

DISEASE, THROUGH 2017 ($ MILLIONS) 6

TABLE 1 MARKETED ASTHMA AND COPD DRUG CLASSES 20

TABLE 2 NET REVENUES FOR TOP SIX ASTHMA/COPD PRODUCT MANUFACTURERS, WITH

PRODUCT(S), 2010 AND 2011 ($ MILLIONS) 29

TABLE 3 NET REVENUES FOR TOP SPECIALTY ASTHMA/COPD MANUFACTURERS WITH

PRODUCT(S), 2010 AND 2011 ($ MILLIONS) 30

TABLE 4 NET REVENUES FOR SMALLER ASTHMA/COPD PRODUCT MANUFACTURER, WITH

PRODUCT, 2010 AND 2011 ($ MILLIONS) 30

TABLE 5 ACQUISITIONS AND MERGERS IN THE ASTHMA AND COPD MARKET, JANUARY 2008

TO JUNE 2012 ($ MILLIONS) 31

TABLE 6 MAJOR ASTHMA/COPD DRUGS THAT LOSE PATENT PROTECTION BETWEEN 2008

AND 2024 35

TABLE 7 ASTHMA AND COPD SYMPTOM COMPARISONS 42

TABLE 8 CLASSIFICATION OF ASTHMA, BY SYMPTOMS 44

TABLE 9 ASTHMA AND COPD DRUG CLASSES 46

TABLE 10 CLASSIFICATION OF COPD AND ASTHMA 49

TABLE 11 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN THE

AMERICAS (%) 54

TABLE 12 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN THE EMRA

(%) 57

TABLE 13 PERCENT OF SELECTED POPULATIONS WITH DIAGNOSED ASTHMA IN ASIA 61

TABLE 14 PROJECTED GLOBAL MARKET FOR ASTHMA AND COPD DRUG, BY DRUG CLASS,

THROUGH 2017 ($ MILLIONS) 63

TABLE 15 PROJECTED GLOBAL MARKET FOR BRONCHODILATORS, THROUGH 2017 ($

MILLIONS) 65

TABLE 16 SHORT-ACTING BETA-2 AGONISTS, WITH APPROVAL AND PATENT EXPIRY DATES,

2011 67

TABLE 17 PROJECTED MARKET FOR SHORT-ACTING BETA-2 AGONIST BRONCHODILATORS,

THROUGH 2017 ($ MILLIONS) 68

TABLE 18 LONG-ACTING BETA-2 AGONISTS, 2011 69

TABLE 19 PROJECTED GLOBAL MARKET FOR LABA PRODUCTS, THROUGH 2017 ($ MILLIONS) 70

TABLE 20 ANTICHOLINERGICS AND COMBINATION ANTICHOLINERGICS/SABA BY

MANUFACTURER, 2011 71

TABLE 21 PROJECTED GLOBAL MARKET FOR ANTICHOLINERGICS, THROUGH 2017 ($

MILLIONS) 72

TABLE 22 PROJECTED GLOBAL MARKET FOR ANTI-INFLAMMATORY DRUGS BY TYPE,

THROUGH 2017 ($ MILLIONS) 74

TABLE 23 INHALED CORTICOSTERIODS, 2011 75

TABLE 24 PROJECTED GLOBAL MARKET FOR INHALED CORTICOSTEROIDS, THROUGH 2017

($ MILLIONS) 77

TABLE 25 LEUKOTRIENE MODIFIERS, 2011 77

TABLE 26 PROJECTED GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, THROUGH 2017 ($

MILLIONS) 78

TABLE 27 PROJECTED GLOBAL MARKET FOR PDE-4 DRUGS, THROUGH 2017 ($ MILLIONS) 80

TABLE 28 PROJECTED GLOBAL MARKET FOR ASTHMA BIOLOGICAL DRUGS, THROUGH 2017

($ MILLIONS) 81

TABLE 29 COMBINATION ICS/LABA DRUGS, 2011 81

TABLE 30 PROJECTED GLOBAL MARKET FOR COMBINATION ICS/LABA DRUGS, THROUGH

2017 ($ MILLIONS) 82

TABLE 31 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS BY REGION, THROUGH 2017

($ MILLIONS) 85

TABLE 32 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE AMERICAS REGION,

THROUGH 2017 ($ MILLIONS) 85

TABLE 33 PROJECTED USE OF ASTHMA/COPD DRUGS IN THE AMERICAS' REGION, THROUGH

2017 ($ MILLIONS) 86

TABLE 34 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE EMRA, THROUGH

2017 ($ MILLIONS) 87

TABLE 35 PROJECTED USE OF ASTHMA/COPD DRUGS IN THE EMRA REGION, THROUGH 2017

($ MILLIONS) 87

TABLE 36 PROJECTED REVENUES FROM ASTHMA/COPD DRUGS IN THE ASIAN REGION,

THROUGH 2017 ($ MILLIONS) 89

TABLE 37 PROJECTED USE OF ASTHMA/COPD DRUGS, BY REGION IN ASIA, THROUGH 2017 ($

MILLIONS) 89

TABLE 38 PROJECTED GLOBAL MARKET FOR ASTHMA PRESCRIPTION DRUGS, THROUGH

2017 ($ MILLIONS) 96

TABLE 39 PROJECTED GLOBAL MARKET FOR COPD PRESCRIPTION DRUGS, THROUGH 2017

($ MILLIONS) 97

TABLE 40 PROJECTED GLOBAL MARKET FOR COMBINATION ASTHMA/COPD DRUGS,

THROUGH 2017 ($ MILLIONS) 98

TABLE 41 PROJECTED GLOBAL MARKET FOR COMBINATION ASTHMA/COPD PRESCRIPTION

DRUGS, THROUGH 2017 ($ MILLIONS) 99

TABLE 42 ASTHMA/COPD PRODUCTS UNDER DEVELOPMENT, BY COMPANY, 2012 106

TABLE 43 APPROVED DRUGS TO TREAT ASTHMA AND COPD, 1996 THROUGH 2011 110

TABLE 44 DRUGS SEEKING APPROVAL TO TREAT ASTHMA AND COPD 2012 THROUGH 2013 111

TABLE 45 ASTHMA/COPD TREATMENT PATENTS, BY COMPANY, DISEASE, PATENT NUMBER,

YEAR FILED, 2011 THROUGH 2012 112

TABLE 46 ASTHMA/COPD TREATMENT PATENTS, BY NUMBER, COMPANY, DESCRIPTION,

AND DATE ISSUED, 2011 THROUGH 2012 115

TABLE 47 ASTHMA/COPD DRUG TREATMENT PATENTS ISSUED BETWEEN JANUARY 2011

AND MAY 2012, BY COMPANY 123

 

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY

REGION, 2012 AND 2017 (%) 6

FIGURE 1 GLOBAL BRONCHODILATOR MARKET, BY TYPE, 2012 AND 2017 (%) 64

FIGURE 2 GLOBAL MARKET SHARE FOR BRONCHODILATORS BY COMPANY, 2011 (%) 65

FIGURE 3 MARKET SHARE FOR LABA BRONCHODILATORS BY COMPANY, 2011 (%) 70

FIGURE 4 MARKET SHARE OF ANTI-INFLAMMATORY DRUGS BY TYPE, 2012 AND 2017 (%) 72

FIGURE 5 MARKET SHARE OF LEADING MANUFACTURERS OF INHALED CORTICOSTERIODS,

2011 (%) 76

FIGURE 6 GLOBAL MARKET FOR LEUKOTRIENE MODIFIERS, BY MANUFACTURER, 2012 AND

2017 (%) 79

FIGURE 7 MARKET SHARE OF MANUFACTURERS OF ICS/LABA, 2011 (%) 83

FIGURE 8 MARKET PERCENT OF ASTHMA/COPD DRUGS IN THE AMERICAS REGION, 2012

AND 2017 (%) 86

FIGURE 9 MARKET PERCENT OF ASTHMA/COPD DRUGS IN THE EMRA, 2012 AND 2017 (%) 88

FIGURE 10 MARKET PERCENTAGE OF ASTHMA/COPD DRUGS, BY REGION IN ASIA, 2012 AND

2017 (%) 89

FIGURE 11 GLOBAL MARKET FOR ASTHMA AND COPD PRESCRIPTION DRUGS BY DISEASE,

2011 (%) 92

FIGURE 12 MARKET SHARES OF LEADING MANUFACTURERS OF ASTHMA DRUGS, 2011 (%) 93

FIGURE 13 MARKET SHARES OF LEADING MANUFACTURERS OF COPD DRUGS, 2011 (%) 96

FIGURE 14 MARKET SHARES OF LEADING MANUFACTURERS OF COMBINATION

ASTHMA/COPD DRUGS, 2011 (%) 98

FIGURE 15 PERCENT OF REVIEWED PATENTS FOR ASTHMA, COPD, AND COMBINATION USE,

JANUARY 2011 TO MAY 2012 (%) 114

FIGURE 16 ASTHMA/COPD PATENTS, BY COUNTRY, 2011 THROUGH 2012 (%) 125

 

 

 

To order this report:

Drug_and_Medication Industry: Global Markets for Asthma and COPD Drugs

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Markets for Membrane Technology for Pharmaceuticals
2. QYresearchReports.com - Global and China Synthesis Polypeptide Drug Industry 2012 Deep Research Report
3. Agricultural Biotechnology: Emerging Technologies and Global Markets
4. Julphar Diabetes Symposium Held with Global Experts in Dubai
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Global Peripheral Vascular Devices Market 2011-2015
7. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
8. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
9. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
10. Ansell Limited and Ramsay Health Care Enter Global Multi-Year Purchasing Agreement
11. Cyberonics To Present At Morgan Stanley 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):